Hemlibra (Emicizumab): Economic Review Report

Details

Files

Project Status:

Completed

Project Line:

Health Technology Review

Project Number:

OB0005-000

This report aims to:

Assess the cost effectiveness of emicizumab (Hemlibra) used as prophylaxis compared with prophylaxis with bypassing agents (BPA) and on-demand (episodic) use of BPAs, in patients hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
Assess, from the Canadian health ministry perspective, the budgetary impact of reimbursing emicizumab, over a three-year period, in patients hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.

Last Updated : September 11, 2019